IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0788007
(2001-02-16)
|
우선권정보 |
JP-0041327 (2000-02-18) |
발명자
/ 주소 |
|
출원인 / 주소 |
- Nippon Zoki Pharmaceutical Co., Ltd.
|
대리인 / 주소 |
Hollander Law Firm, P.L.C.
|
인용정보 |
피인용 횟수 :
9 인용 특허 :
26 |
초록
▼
The present invention provides a composition for enhancing the pharmacological activity of a water-soluble silicate polymer which comprises the water-soluble silicate polymer and a saturated fatty acid in pharmaceutically effective amounts for use as a medicine such as anti-allergic agent. The water
The present invention provides a composition for enhancing the pharmacological activity of a water-soluble silicate polymer which comprises the water-soluble silicate polymer and a saturated fatty acid in pharmaceutically effective amounts for use as a medicine such as anti-allergic agent. The water soluble silicate polymers used according to the present invention may be obtained by polymerization and/or by extraction from plants, animals or fungi, or inflammatory tissue. The saturated fatty acid contained as an effective ingredient in the pharmaceutical composition of the present invention may be a straight chain or branched chain saturated fatty acid having about 8 carbon atoms to about 26 carbon atoms. The saturated fatty acid and water-soluble silicate polymer, effective ingredients of the present invention, can be formulated for various pharmaceutical compositions by combining with a suitable carrier or diluent for medical use. The composition of the present invention can suppress histamine release induced by a structural change in the cell membrane of the mast cell. It exhibits an excellent organism maintaining function such as cell protecting action and, therefore, is useful as a medicine such as an anti-allergic or anti-inflammatory agent.
대표청구항
▼
The present invention provides a composition for enhancing the pharmacological activity of a water-soluble silicate polymer which comprises the water-soluble silicate polymer and a saturated fatty acid in pharmaceutically effective amounts for use as a medicine such as anti-allergic agent. The water
The present invention provides a composition for enhancing the pharmacological activity of a water-soluble silicate polymer which comprises the water-soluble silicate polymer and a saturated fatty acid in pharmaceutically effective amounts for use as a medicine such as anti-allergic agent. The water soluble silicate polymers used according to the present invention may be obtained by polymerization and/or by extraction from plants, animals or fungi, or inflammatory tissue. The saturated fatty acid contained as an effective ingredient in the pharmaceutical composition of the present invention may be a straight chain or branched chain saturated fatty acid having about 8 carbon atoms to about 26 carbon atoms. The saturated fatty acid and water-soluble silicate polymer, effective ingredients of the present invention, can be formulated for various pharmaceutical compositions by combining with a suitable carrier or diluent for medical use. The composition of the present invention can suppress histamine release induced by a structural change in the cell membrane of the mast cell. It exhibits an excellent organism maintaining function such as cell protecting action and, therefore, is useful as a medicine such as an anti-allergic or anti-inflammatory agent. GLYOL 810, capric-caprylic triglyceride, soybean oil, and mixtures thereof.5. The dispersion of claim 1, wherein the amphiphilic agent is selected from the group consisting of pharmaceutically acceptable phospholipids, pharmaceutically acceptable lecithins, and mixtures thereof.6. The dispersion of claim 1, wherein the amphiphilic agent is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy lecithin, soy phosphatidylcholine, 1,2-dimyristoyl-sn-glycero-3-phosphotidlycholine (DMPC), 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DMPG), L-alpha-phosphatidylcholine, palmitoyl-linoleoyl phosphatidylcholine, stearoyl-linoleoyl phosphatidylcholine, lysolecithin, phosphatidic acid, phosphatidyl-DL-glycerol, phosphatidylethanolamine, palmitoyl-oleoyl phosphatidylcholine, phosphatidylinositol, phosphatidylserine, 1,3-bis(sn-3-phosphatidyl)-sn-glycerol, 1,3-di(3-sn-phosphatidyl)-sn-glycerol, and mixtures thereof.7. The dispersion of claim 1, wherein the amphiphilic agent comprises a surfactant selected from the group consisting of a pharmaceutically acceptable non-ionic surfactant, a pharmaceutically acceptable ionic surfactant, and mixtures thereof.8. The dispersion of claim 1, wherein the hydroxyl-group-containing excipient is selected from the group consisting of a monosaccharide, a disaccharide, a trisaccharide, sucrose, dextrose, trehalose, mannitol, lactose, glycerol, glycerin, sorbitol, and mixtures thereof.9. The dispersion of claim 1, wherein the antimicrobial agent is selected from the group consisting of benzoic acid, benzyl alcohol, chlorobutanol, chlorocresol, cresol, dehydroacetic acid, phenol, phenylethyl alcohol, potassium benzoate, potassium sorbate, sodium benzoate, sodium dehydroacetate, sodium propionate, sorbic acid, and thymol, and mixtures thereof.10. The dispersion of claim 1, wherein the antimicrobial agent is selected from the group consisting of benzalkonium chloride, benzethonium chloride, butyl paraben, cetylpyridinium chloride, ethylparaben, methylparaben, methylparaben sodium, propylparaben, and propylparaben sodium, and mixtures thereof.11. The dispersion of claim 1, wherein propofol is present in an amount of from about 2% to about 5%.12. The dispersion of claim 11, wherein propofol is present in an amount of about 2%.13. The dispersion of claim 1, wherein the hydroxyl-group-containing excipient is mannitol.14. The dispersion of claim 13, wherein mannitol is present in an amount of from about 5.5% to about 7.5%.15. The dispersion of claim 14, wherein mannitol is present in an amount of about 5.5%.16. The dispersion of claim 1, wherein the propofol-soluble diluent is a medium chain triglyceride.17. The dispersion of claim 16, wherein the medium chain triglyceride is a triglyceride of a C-8 to C-12 saturated or unsaturated pharmaceutically acceptable fatty acid.18. The dispersion of claim 17, wherein the medium chain triglyceride is capric-caprylic triglyceride.19. The dispersion of claim 18, wherein the medium chain triglyceride is MIGLYOL 810.20. The dispersion of claim 16, wherein the medium chain triglyceride is present in an amount of from about 1% to about 4%.21. The dispersion of claim 20, wherein the medium chain triglyceride is present in an amount of from about 2% to about 4%.22. The dispersion of claim 21, wherein the medium chain triglyceride is present in an amount of about 4%.23. The dispersion of claim 1, wherein the amphiphilic agent is egg lecithin.24. The dispersion of claim 23, wherein the egg lecithin is present in an amount of from about 1.5% to about 5%.25. The dispersion of claim 24, wherein the egg lecithin is present in an amount of from about 0.67% to about 2.5%.26. The dispersion of claim 25, wherein the egg lecithin is present in an amount of about 1.6%.27. The dispersion of claim 1, which includes anionic dimyristoylphosphatidyl glycerol.28. The dispersion of claim 27, wherein the anionic dimyristoylphosphatidyl glycerol is present in an am
※ AI-Helper는 부적절한 답변을 할 수 있습니다.